Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease

November 18, 2013 updated by: Boehringer Ingelheim

Application of the WHO-5 Well-being Index (WHO-5) as a Screening Instrument for Depression in Parkinson's Disease

To assess the predictive value of sequential administration of WHO-5 and MDI (Major Depression Inventory) for the clinical management of Parkinson Disease (PD) patients by

determination of the prevalence of depression in PD patients, based on MDI severity categories and the self-rating scale WHO-5, where poor well being was indicated.
exploration of influencing factors (PD status, therapeutic status) on the prevalence of MDI depression categories.

Study Overview

Status

Completed

Conditions

Parkinson Disease

Study Type

Observational

Enrollment (Actual)

1588

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Germany
- - Achim, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Achim, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Altenburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Altenholz, Germany
    - Boehringer Ingelheim Investigational Site
  - Alzey, Germany
    - Boehringer Ingelheim Investigational Site
  - Aue, Germany
    - Boehringer Ingelheim Investigational Site
  - Bad Driburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Bad Homburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Bad Honnef, Germany
    - Boehringer Ingelheim Investigational Site
  - Bad Neuenahr-Ahrweiler, Germany
    - Boehringer Ingelheim Investigational Site
  - Bad Soden, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Bad Soden, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Bad Sooden-Allendorf, Germany
    - Boehringer Ingelheim Investigational Site
  - Bergisch Gladbach, Germany
    - Boehringer Ingelheim Investigational Site
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 10
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 11
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 14
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 5
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 8
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 9
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 12
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 13
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 6
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 7
  - Berlin, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Bielefeld, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Bielefeld, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Bochum, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Bochum, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Bochum, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Bockhorn, Germany
    - Boehringer Ingelheim Investigational Site
  - Bonn, Germany
    - Boehringer Ingelheim Investigational Site
  - Braunschweig, Germany
    - Boehringer Ingelheim Investigational Site
  - Bremen, Germany
    - Boehringer Ingelheim Investigational Site
  - Bremerhaven, Germany
    - Boehringer Ingelheim Investigational Site
  - Bretten, Germany
    - Boehringer Ingelheim Investigational Site
  - Butzbach, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Butzbach, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Buxtehude, Germany
    - Boehringer Ingelheim Investigational Site
  - Castrop-Rauxel, Germany
    - Boehringer Ingelheim Investigational Site
  - Chemnitz, Germany
    - Boehringer Ingelheim Investigational Site
  - Cloppenburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Coesfeld, Germany
    - Boehringer Ingelheim Investigational Site
  - Cottbus, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Cottbus, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Delmenhorst, Germany
    - Boehringer Ingelheim Investigational Site
  - Dessau, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Dessau, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Dietzenbach, Germany
    - Boehringer Ingelheim Investigational Site
  - Dippoldiswalde, Germany
    - Boehringer Ingelheim Investigational Site
  - Dortmund, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Dortmund, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Dortmund, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Dresden, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Dresden, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Dresden, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Dresden, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Duisburg, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Duisburg, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Duisburg, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Duisburg, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Dülmen, Germany
    - Boehringer Ingelheim Investigational Site
  - Düsseldorf, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Düsseldorf, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Düsseldorf, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Düsseldorf, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Düsseldorf, Germany
    - Boehringer Ingelheim Investigational Site 5
  - Erbach, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Erbach, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Erftstadt, Germany
    - Boehringer Ingelheim Investigational Site
  - Essen, Germany
    - Boehringer Ingelheim Investigational Site
  - Frankfurt, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Frankfurt, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Freiburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Fürstenwalde, Germany
    - Boehringer Ingelheim Investigational Site
  - Gelnhausen, Germany
    - Boehringer Ingelheim Investigational Site
  - Gelsenkirchen, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Gelsenkirchen, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Gengenbach, Germany
    - Boehringer Ingelheim Investigational Site
  - Gera, Germany
    - Boehringer Ingelheim Investigational Site
  - Gießen, Germany
    - Boehringer Ingelheim Investigational Site
  - Gifhorn, Germany
    - Boehringer Ingelheim Investigational Site
  - Gladenbach, Germany
    - Boehringer Ingelheim Investigational Site
  - Goch, Germany
    - Boehringer Ingelheim Investigational Site
  - Grünstadt, Germany
    - Boehringer Ingelheim Investigational Site
  - Göttingen, Germany
    - Boehringer Ingelheim Investigational Site
  - Güstrow, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Güstrow, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Gütersloh, Germany
    - Boehringer Ingelheim Investigational Site
  - Halle, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Halle, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Halle, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Hamburg, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Hamburg, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Hamburg, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Hamburg, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Hamburg, Germany
    - Boehringer Ingelheim Investigational Site 5
  - Hameln, Germany
    - Boehringer Ingelheim Investigational Site
  - Hannover, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Hannover, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Hannover, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Hannover, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Heidelberg, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Heidelberg, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Heilbronn, Germany
    - Boehringer Ingelheim Investigational Site
  - Hemmoor, Germany
    - Boehringer Ingelheim Investigational Site
  - Hennigsdorf, Germany
    - Boehringer Ingelheim Investigational Site
  - Henstedt-Ulzburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Herborn, Germany
    - Boehringer Ingelheim Investigational Site
  - Herzberg, Germany
    - Boehringer Ingelheim Investigational Site
  - Herzogenrath, Germany
    - Boehringer Ingelheim Investigational Site
  - Hildesheim, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Hildesheim, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Hildesheim, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Hildesheim, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Hildesheim, Germany
    - Boehringer Ingelheim Investigational Site 5
  - Homburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Hückelhoven, Germany
    - Boehringer Ingelheim Investigational Site
  - Hürth, Germany
    - Boehringer Ingelheim Investigational Site
  - Ilmenau, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Ilmenau, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Ingelheim, Germany
    - Boehringer Ingelheim Investigational Site
  - Iserlohn, Germany
    - Boehringer Ingelheim Investigational Site
  - Itzehoe, Germany
    - Boehringer Ingelheim Investigational Site
  - Kamen, Germany
    - Boehringer Ingelheim Investigational Site
  - Kamp-Lintfort, Germany
    - Boehringer Ingelheim Investigational Site
  - Kandel, Germany
    - Boehringer Ingelheim Investigational Site
  - Karlstadt, Germany
    - Boehringer Ingelheim Investigational Site
  - Kassel, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Kassel, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Kaufbeuren, Germany
    - Boehringer Ingelheim Investigational Site
  - Kiel, Germany
    - Boehringer Ingelheim Investigational Site
  - Kleinblittersdorf, Germany
    - Boehringer Ingelheim Investigational Site
  - Kleve, Germany
    - Boehringer Ingelheim Investigational Site
  - Köln, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Köln, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Köln, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Köln, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Köln, Germany
    - Boehringer Ingelheim Investigational Site 5
  - Köln, Germany
    - Boehringer Ingelheim Investigational Site 6
  - Köln, Germany
    - Boehringer Ingelheim Investigational Site 7
  - Lappersdorf, Germany
    - Boehringer Ingelheim Investigational Site
  - Lauterbach, Germany
    - Boehringer Ingelheim Investigational Site
  - Leer, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Leer, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Leipzig, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Leipzig, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Leipzig, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Leipzig, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Leipzig, Germany
    - Boehringer Ingelheim Investigational Site 5
  - Leverkusen, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Leverkusen, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Ludwigsfelde, Germany
    - Boehringer Ingelheim Investigational Site
  - Ludwigshafen, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Ludwigshafen, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Ludwigshafen, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Ludwigslust, Germany
    - Boehringer Ingelheim Investigational Site
  - Löbau, Germany
    - Boehringer Ingelheim Investigational Site
  - Lüdenscheid, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Lüdenscheid, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Lüdenscheid, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Lüdenscheid, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Lüdenscheid, Germany
    - Boehringer Ingelheim Investigational Site 5
  - Lüneburg, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Lüneburg, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Lünen, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Lünen, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Magdeburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Malente, Germany
    - Boehringer Ingelheim Investigational Site
  - Mannheim, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Mannheim, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Mannheim, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Mannheim, Germany
    - Boehringer Ingelheim Investigational Site 4
  - Markkleeberg, Germany
    - Boehringer Ingelheim Investigational Site
  - Marl, Germany
    - Boehringer Ingelheim Investigational Site
  - Memmingen, Germany
    - Boehringer Ingelheim Investigational Site
  - Menden, Germany
    - Boehringer Ingelheim Investigational Site
  - Mittweida, Germany
    - Boehringer Ingelheim Investigational Site
  - Mönchengladbach, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Mönchengladbach, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Mönchengladbach, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Mühlacker, Germany
    - Boehringer Ingelheim Investigational Site
  - Mülheim, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Mülheim, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Mülheim, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Münster, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Münster, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Münster, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Naumburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Neubrandenburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Neuenhagen, Germany
    - Boehringer Ingelheim Investigational Site
  - Neukirchen-Vluyn, Germany
    - Boehringer Ingelheim Investigational Site
  - Neumünster, Germany
    - Boehringer Ingelheim Investigational Site
  - Neustadt, Germany
    - Boehringer Ingelheim Investigational Site
  - Norden, Germany
    - Boehringer Ingelheim Investigational Site
  - Nordhorn, Germany
    - Boehringer Ingelheim Investigational Site
  - Nübel, Germany
    - Boehringer Ingelheim Investigational Site
  - Oberndorf, Germany
    - Boehringer Ingelheim Investigational Site
  - Offenbach, Germany
    - Boehringer Ingelheim Investigational Site
  - Oldenburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Oranienburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Oschatz, Germany
    - Boehringer Ingelheim Investigational Site
  - Osnabrück, Germany
    - Boehringer Ingelheim Investigational Site
  - Paderborn, Germany
    - Boehringer Ingelheim Investigational Site
  - Pirmasens, Germany
    - Boehringer Ingelheim Investigational Site
  - Plauen, Germany
    - Boehringer Ingelheim Investigational Site
  - Potsdam, Germany
    - Boehringer Ingelheim Investigational Site
  - Quakenbrück, Germany
    - Boehringer Ingelheim Investigational Site
  - Rastatt, Germany
    - Boehringer Ingelheim Investigational Site
  - Rathenow, Germany
    - Boehringer Ingelheim Investigational Site
  - Regensburg, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Regensburg, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Remscheid, Germany
    - Boehringer Ingelheim Investigational Site
  - Rendsburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Rheine, Germany
    - Boehringer Ingelheim Investigational Site
  - Ribnitz-Damgarten, Germany
    - Boehringer Ingelheim Investigational Site
  - Riesa, Germany
    - Boehringer Ingelheim Investigational Site
  - Rostock, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Rostock, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Rostock, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Rödermark, Germany
    - Boehringer Ingelheim Investigational Site
  - Rüdersdorf, Germany
    - Boehringer Ingelheim Investigational Site
  - Rüsselsheim, Germany
    - Boehringer Ingelheim Investigational Site
  - Salzgitter, Germany
    - Boehringer Ingelheim Investigational Site
  - Schirgiswalde, Germany
    - Boehringer Ingelheim Investigational Site
  - Schleiden, Germany
    - Boehringer Ingelheim Investigational Site
  - Schriesheim, Germany
    - Boehringer Ingelheim Investigational Site
  - Schwelm, Germany
    - Boehringer Ingelheim Investigational Site
  - Schwerin, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Schwerin, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Seeheim-Jugenheim, Germany
    - Boehringer Ingelheim Investigational Site
  - Senftenberg, Germany
    - Boehringer Ingelheim Investigational Site
  - Solingen, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Solingen, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Solingen, Germany
    - Boehringer Ingelheim Investigational Site 3
  - Stade, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Stade, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Stollberg, Germany
    - Boehringer Ingelheim Investigational Site
  - Stralsund, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Stralsund, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Strausberg, Germany
    - Boehringer Ingelheim Investigational Site
  - Sömmerda, Germany
    - Boehringer Ingelheim Investigational Site
  - Telgte, Germany
    - Boehringer Ingelheim Investigational Site
  - Teltow, Germany
    - Boehringer Ingelheim Investigational Site
  - Torgau, Germany
    - Boehringer Ingelheim Investigational Site
  - Trier, Germany
    - Boehringer Ingelheim Investigational Site
  - Troisdorf, Germany
    - Boehringer Ingelheim Investigational Site
  - Vechta, Germany
    - Boehringer Ingelheim Investigational Site
  - Velen, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Velen, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Verden, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Verden, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Viersen, Germany
    - Boehringer Ingelheim Investigational Site
  - Villingen-Schwenningen, Germany
    - Boehringer Ingelheim Investigational Site
  - Voerde, Germany
    - Boehringer Ingelheim Investigational Site
  - Warendorf, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Warendorf, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Wedel, Germany
    - Boehringer Ingelheim Investigational Site
  - Weida, Germany
    - Boehringer Ingelheim Investigational Site
  - Weil am Rhein, Germany
    - Boehringer Ingelheim Investigational Site
  - Weißenfels, Germany
    - Boehringer Ingelheim Investigational Site
  - Werdau, Germany
    - Boehringer Ingelheim Investigational Site
  - Wesseling, Germany
    - Boehringer Ingelheim Investigational Site
  - Wetzlar, Germany
    - Boehringer Ingelheim Investigational Site
  - Weyhe, Germany
    - Boehringer Ingelheim Investigational Site
  - Wismar, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Wismar, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Wolfratshausen, Germany
    - Boehringer Ingelheim Investigational Site
  - Wolgast, Germany
    - Boehringer Ingelheim Investigational Site
  - Wunstorf, Germany
    - Boehringer Ingelheim Investigational Site
  - Wuppertal, Germany
    - Boehringer Ingelheim Investigational Site 1
  - Wuppertal, Germany
    - Boehringer Ingelheim Investigational Site 2
  - Würzburg, Germany
    - Boehringer Ingelheim Investigational Site
  - Zella-Mehlis, Germany
    - Boehringer Ingelheim Investigational Site
  - Zwickau, Germany
    - Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

resident physician

Description

Inclusion Criteria:

PD patients attending one of the participating neurologist practices during 2 fixed weeks in November 2008
Idiopathic PD with or without fluctuations
Male or female PD patients aged at least 30
Ability to reliably complete self-rating scales (WHO-5, MDI) ), according to the physician's judgement.
Written informed consent by the patient for study participation.

Exclusion Criteria:

PD Patients who only attend the practice to get a prescription and are not seen by the doctor on that day
Patients who are not able to understand the questionnaires (e.g. due to mental impairment or language problems).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Prevalence of patients with depressive symptoms (based on WHO-5 and MDI) in total and in subgroups Time Frame: day 1	day 1

Secondary Outcome Measures

Outcome Measure	Time Frame
WHO-5 score and items Time Frame: day 1	day 1
MDI score (for a subgroup of patients with WHO-5 score < 13 or any WHO-5 item rated with 0 or 1) Time Frame: day 1	day 1
Correlation of WHO-5 and MDI (for a subgroup of patients with a WHO-5 score < 13 or any WHO-5 item rated with 0 or 1) in PD patients Time Frame: day 1	day 1
Investigator assessment of the applicability of the WHO-5 for screening for depression in PD patients Time Frame: day 1	day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2008

Primary Completion (Actual)

November 1, 2008

Study Registration Dates

First Submitted

September 12, 2008

First Submitted That Met QC Criteria

September 12, 2008

First Posted (Estimate)

September 15, 2008

Study Record Updates

Last Update Posted (Estimate)

November 19, 2013

Last Update Submitted That Met QC Criteria

November 18, 2013

Last Verified

November 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

248.658

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

National Heart, Lung, and Blood Institute (NHLBI)

Completed

Hereditary Parkinson s Disease Natural History Protocol

Parkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1

United States
ProgenaBiome

Recruiting

A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease

Parkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4

United States
King's College London
GlaxoSmithKline

Completed

Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease

Parkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8

United Kingdom
Ohio State University

Completed

PA Behavior and HRQoL in Parkinson's Disease Patients Patients: Role of Social Cognitive Variables (PDQ)

Parkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, Idiopathic

United States
National Yang Ming University

Unknown

Dual-task Performance in Young-onset PD

Early Onset Parkinson Disease | Early Stage Parkinson Disease
Michele Tagliati, MD

Recruiting

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

REM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson Disease

United States
Cedars-Sinai Medical Center

Enrolling by invitation

Cardiac Changes in Early Parkinson's Disease: A Follow up Study

REM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson Disease

United States
Mahatma Gandhi Institute of Medical Sciences

Completed

Challenges Faced By Neurophysiotherapist While Consultation Through Tele-rehabilitation

Stroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitation

India
Merck Sharp & Dohme LLC

Completed

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
University of Deusto

Completed

Improving Functional Disability and Cognition in Parkinson Disease: Randomized Controlled Trial

PARKINSON DISEASE (Disorder)

Spain

Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease

Application of the WHO-5 Well-being Index (WHO-5) as a Screening Instrument for Depression in Parkinson's Disease

Study Overview

Status

Conditions

Study Type

Enrollment (Actual)

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Sampling Method

Study Population

Description

Study Plan

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Time Frame

Secondary Outcome Measures

Outcome Measure

Time Frame

Collaborators and Investigators

Sponsor

Study record dates

Study Major Dates

Study Start

Primary Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Estimate)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Clinical Trials on Parkinson Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations